Imatinib activity on Schistosoma mansoni.

Submitted by Nuzia Santos ([email protected]) on 2018-12-19T11:45:28Z No. of bitstreams: 1 Imatinib activity on Schistosoma mansoni.pdf: 3737799 bytes, checksum: 2026a4b57def5ecd323c0f6e54e59aa6 (MD5)Approved for entry into archive by Nuzia Santos ([email protected]) on 2018-12-19T11:48:26Z (GMT) No. of bitstreams: 1 Imatinib activity on Schistosoma mansoni.pdf: 3737799 bytes, checksum: 2026a4b57def5ecd323c0f6e54e59aa6 (MD5)Made available in DSpace on 2018-12-19T11:48:26Z (GMT). No. of bitstreams: 1 Imatinib activity on Schistosoma mansoni.pdf: 3737799 bytes, checksum: 2026a4b57def5ecd323c0f6e54e59aa6 (MD5) Previous issue date: 2013Fundação Oswaldo Cruz. Centro de Pesquisas René Rachou. Laboratório de Esquistossomose. Belo Horizonte, MG, Brasil/Academia Mineira de Medicina. Belo Horizonte, MG, BrasilFundação Oswaldo Cruz. Centro de Pesquisas René Rachou. Laboratório de Esquistossomose. Belo Horizonte, MG, BrasilFundação Oswaldo Cruz. Centro de Pesquisas René Rachou. Laboratório de Esquistossomose. Belo Horizonte, MG, BrasilImatinib, a drug used for treatment of human chronic myeloid leukaemia, due to its activity against protein kinases, has been also evaluated in vitro against Schistosoma mansoni showing high schistosomicidal activity. In the present experiments imatinib activity in vitro was confirmed at the doses of 25 µM, 50 µM and 100 µM. The first drug activity observed with the lower dose was interruption of egg-laying and with the higher dosages was the death of the worms. In mice infected with S. mansoni no activity was found even with 1,000 mg/kg/day, 500 mg/kg/day, single oral dose or when administered for three consecutive days. This is another example of the difference of results related to in vitro and in vivo trials using S. mansoni worms